 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome : |
(King's College London) (Institut Jêrome Lejeune) (Institut Jêrome Lejeune) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Institut de Recerca Sant Pau) (Aristotle University of Thessaloniki)| Data: | 2025 |
| Resum: | INTRODUCTION: The Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS) is a sensitive cognitive test for Alzheimer's disease (AD)-related decline in people with DS, but needs updates for sensitivity, cultural adaptability, and additional memory/executive function items. This study aimed to develop and validate the CAMCOG-DS-II. METHODS: In this multi-language, multi-site study, the psychometric properties of the CAMCOG-DS-II were evaluated against previously validated measures in 223 participants (mean age: 40. 18 years) with DS across seven countries. RESULTS: The CAMCOG-DS-II had a high completion rate, minimal floor/ceiling effects (compared to the modified Cued Recall Test, the CANTAB Paired Associates Learning, and the Purdue Pegboard), strong validity and reliability, and performance was unaffected by language across sites. It differentiated between those with/without AD and distinguished clinically rated cognitively stable and prodromal individuals. CONCLUSION: The CAMCOG-DS-II is a sensitive measure of cognitive performance in people with DS at risk of AD. Its cross-language and site reliability support its potential use in AD-DS clinical trials. Highlights: Developed and validated the Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS-II) for Alzheimer's disease in Down syndrome. CAMCOG-DS-II shows increased sensitivity to Alzheimer's disease-related decline in Down syndrome. Improved applicability across an international and culturally diverse population. Differentiates Alzheimer's disease status: cognitively stable, prodromal, and clinical. |
| Ajuts: | Instituto de Salud Carlos III PI20/01473 Instituto de Salud Carlos III PI23/01786 Instituto de Salud Carlos III PI18/00335 Instituto de Salud Carlos III ICI23/00032 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Alzheimer's disease ; Down syndrome ; Cognitive decline ; Cognitive testing ; Trisomy 21 |
| Publicat a: | Alzheimer's & dementia, Vol. 21 Núm. 3 (march 2025) , p. e70071, ISSN 1552-5279 |
